Aroa Biosurgery (ARX) Aktienübersicht
Aroa Biosurgery Limited entwickelt, produziert und vertreibt medizinische Geräte für die Reparatur von Wunden und Weichgewebe unter Verwendung der Extrazellularmatrix (ECM)-Technologie in den Vereinigten Staaten und international. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 2/6 |
| Künftiges Wachstum | 4/6 |
| Vergangene Leistung | 3/6 |
| Finanzielle Gesundheit | 6/6 |
| Dividenden | 0/6 |
ARX Community Fair Values
Create NarrativeSee what 50 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Aroa Biosurgery Limited Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | AU$0.56 |
| 52-Wochen-Hoch | AU$0.80 |
| 52-Wochen-Tief | AU$0.49 |
| Beta | 0.85 |
| 1 Monat Veränderung | -12.40% |
| 3 Monate Veränderung | 2.73% |
| 1 Jahr Veränderung | -3.42% |
| 3 Jahre Veränderung | -35.80% |
| 5 Jahre Veränderung | -52.92% |
| Veränderung seit IPO | -58.15% |
Aktuelle Nachrichten und Updates
ARX: Positive Trial Success And Growing Portfolio Will Support Future Earnings Power
Analysts have maintained their Aroa Biosurgery fair value estimate at A$1.09. They applied a slightly higher discount rate and made only minor adjustments to revenue growth, profit margin and future P/E assumptions to support their unchanged price target view.ARX: Positive Trial Results Will Underpin Future Earnings Power
Analysts have nudged their price target for Aroa Biosurgery higher to A$1.09 from A$1.07, reflecting updated assumptions around discount rates, revenue growth, profit margins, and future P/E expectations. What's in the News Aroa Biosurgery issued earnings guidance for fiscal 2026, projecting total revenue of about NZ$104 million on an actual basis, citing stronger than expected sales in the Myriad portfolio and favourable foreign exchange movements.ARX: Positive Wound Trial Results Will Support Stronger Future Profitability
Analysts have lifted their price target for Aroa Biosurgery from A$0.83 to A$1.07, citing updated assumptions that include a higher discount rate, a slightly adjusted revenue growth outlook, a stronger forecast profit margin, and a lower future P/E multiple. What's in the News Aroa Biosurgery reported completion of its randomised controlled trial of Symphony, a skin substitute designed for hard to heal wounds such as diabetic foot ulcers and venous leg ulcers, with a preliminary read out indicating the primary endpoint was achieved (Key Developments).Recent updates
ARX: Positive Trial Success And Growing Portfolio Will Support Future Earnings Power
Analysts have maintained their Aroa Biosurgery fair value estimate at A$1.09. They applied a slightly higher discount rate and made only minor adjustments to revenue growth, profit margin and future P/E assumptions to support their unchanged price target view.ARX: Positive Trial Results Will Underpin Future Earnings Power
Analysts have nudged their price target for Aroa Biosurgery higher to A$1.09 from A$1.07, reflecting updated assumptions around discount rates, revenue growth, profit margins, and future P/E expectations. What's in the News Aroa Biosurgery issued earnings guidance for fiscal 2026, projecting total revenue of about NZ$104 million on an actual basis, citing stronger than expected sales in the Myriad portfolio and favourable foreign exchange movements.ARX: Positive Wound Trial Results Will Support Stronger Future Profitability
Analysts have lifted their price target for Aroa Biosurgery from A$0.83 to A$1.07, citing updated assumptions that include a higher discount rate, a slightly adjusted revenue growth outlook, a stronger forecast profit margin, and a lower future P/E multiple. What's in the News Aroa Biosurgery reported completion of its randomised controlled trial of Symphony, a skin substitute designed for hard to heal wounds such as diabetic foot ulcers and venous leg ulcers, with a preliminary read out indicating the primary endpoint was achieved (Key Developments).
Reimbursement Shifts And Partner Dependence Will Reshape Tissue Regeneration Prospects Over Time
Catalysts About Aroa Biosurgery Aroa Biosurgery develops and supplies biologically derived soft tissue regeneration products used in wound care, reconstruction and surgical procedures. What are the underlying business or industry changes driving this perspective?
Outpatient Expansion And Surgical Partnerships Will Transform Long Term Prospects For This Biologics Supplier
Catalysts About Aroa Biosurgery Aroa Biosurgery develops and supplies biologically derived soft tissue regeneration products used in wound care, trauma, burns and reconstructive surgery. What are the underlying business or industry changes driving this perspective?Aroa Biosurgery Limited (ASX:ARX) Just Reported Interim Earnings: Have Analysts Changed Their Mind On The Stock?
Aroa Biosurgery Limited ( ASX:ARX ) last week reported its latest half-yearly results, which makes it a good time for...
Lebanon, Vietnam, And Saudi Arabia Approvals Will Secure Market Presence
Expansion into international markets and positive clinical outcomes suggest potential revenue growth as new regions adopt Aroa's cost-effective products.Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 26% Share Price Plunge
Unfortunately for some shareholders, the Aroa Biosurgery Limited ( ASX:ARX ) share price has dived 26% in the last...Aroa Biosurgery (ASX:ARX) Is In A Strong Position To Grow Its Business
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 26% Share Price Plunge
Aroa Biosurgery Limited ( ASX:ARX ) shareholders won't be pleased to see that the share price has had a very rough...Aroa Biosurgery Limited (ASX:ARX) Held Back By Insufficient Growth Even After Shares Climb 26%
Aroa Biosurgery Limited ( ASX:ARX ) shares have continued their recent momentum with a 26% gain in the last month...The Aroa Biosurgery Limited (ASX:ARX) Interim Results Are Out And Analysts Have Published New Forecasts
It's been a good week for Aroa Biosurgery Limited ( ASX:ARX ) shareholders, because the company has just released its...We're Not Worried About Aroa Biosurgery's (ASX:ARX) Cash Burn
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Take Care Before Jumping Onto Aroa Biosurgery Limited (ASX:ARX) Even Though It's 29% Cheaper
Aroa Biosurgery Limited ( ASX:ARX ) shareholders won't be pleased to see that the share price has had a very rough...Investors Aren't Entirely Convinced By Aroa Biosurgery Limited's (ASX:ARX) Revenues
With a price-to-sales (or "P/S") ratio of 3.3x Aroa Biosurgery Limited ( ASX:ARX ) may be sending very bullish signals...Here's Why We're Not At All Concerned With Aroa Biosurgery's (ASX:ARX) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 25% Share Price Plunge
Aroa Biosurgery Limited ( ASX:ARX ) shareholders that were waiting for something to happen have been dealt a blow with...Aroa Biosurgery Limited's (ASX:ARX) Revenues Are Not Doing Enough For Some Investors
With a price-to-sales (or "P/S") ratio of 4.3x Aroa Biosurgery Limited ( ASX:ARX ) may be sending very bullish signals...Industry Analysts Just Made A Captivating Upgrade To Their Aroa Biosurgery Limited (ASX:ARX) Revenue Forecasts
Shareholders in Aroa Biosurgery Limited ( ASX:ARX ) may be thrilled to learn that the analysts have just delivered a...Aroa Biosurgery Limited's (ASX:ARX) Intrinsic Value Is Potentially 50% Above Its Share Price
Does the October share price for Aroa Biosurgery Limited ( ASX:ARX ) reflect what it's really worth? Today, we will...We Think Aroa Biosurgery (ASX:ARX) Can Easily Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Here's What Analysts Are Forecasting For Aroa Biosurgery Limited (ASX:ARX) After Its Annual Results
Investors in Aroa Biosurgery Limited ( ASX:ARX ) had a good week, as its shares rose 6.2% to close at AU$1.20 following...Aktionärsrenditen
| ARX | AU Biotechs | AU Markt | |
|---|---|---|---|
| 7D | -5.8% | 6.3% | 1.0% |
| 1Y | -3.4% | -45.9% | 2.2% |
Rendite im Vergleich zur Industrie: ARX übertraf die Branche Australian Biotechs , die im vergangenen Jahr eine Rendite von -45.9 erzielte.
Rendite vs. Markt: ARX hinter dem Markt Australian zurück, der im vergangenen Jahr eine Rendite von 2.2 erzielte.
Preisvolatilität
| ARX volatility | |
|---|---|
| ARX Average Weekly Movement | 8.1% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 9.7% |
| 10% most volatile stocks in AU Market | 17.1% |
| 10% least volatile stocks in AU Market | 4.0% |
Stabiler Aktienkurs: ARX hatte in den letzten 3 Monaten im Vergleich zum Australian -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: ARXDie wöchentliche Volatilität (8%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 2007 | n/a | Brian Ward | aroa.com |
Aroa Biosurgery Limited entwickelt, produziert und vertreibt Medizinprodukte für die Wund- und Weichgewebereparatur unter Verwendung der Extrazellularmatrix (ECM)-Technologie in den Vereinigten Staaten und international. Zu den Produkten des Unternehmens gehören Endoform Natural und Endoform Antimicrobial Restorative Bioscaffold für die Behandlung akuter und chronischer Wunden; Myriad Matrix, eine speziell entwickelte ECM für die Reparatur und Verstärkung von Weichgewebe und komplexen Wunden; Myriad Morcells, ein morcellisiertes (pulverisiertes) Format von Myriad Matrix für die Reparatur von Weichgewebe und komplexen Wunden; Myriad Morcells Fine, das einen Bolus biologisch wichtiger ECM-Proteine liefert, um die Heilung in Gang zu setzen und aufrechtzuerhalten; und Symphony, ein kombiniertes Zell- und Gewebeprodukt, das für die Regeneration von funktionellem Gewebe bei komplexen Wunden angezeigt ist. Das Unternehmen entwickelt außerdem Produkte für die Rekonstruktion der Bauchdecke, die Reparatur von Hernien und die Brustrekonstruktion in Nordamerika und Europa.
Aroa Biosurgery Limited's Grundlagenzusammenfassung
| ARX grundlegende Statistiken | |
|---|---|
| Marktanteil | AU$197.16m |
| Gewinn(TTM) | AU$3.84m |
| Umsatz(TTM) | AU$85.24m |
Ist ARX zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| ARX Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | NZ$103.85m |
| Kosten der Einnahmen | NZ$15.03m |
| Bruttogewinn | NZ$88.83m |
| Sonstige Ausgaben | NZ$84.15m |
| Gewinn | NZ$4.68m |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | 0.014 |
| Bruttomarge | 85.53% |
| Nettogewinnspanne | 4.50% |
| Schulden/Eigenkapital-Verhältnis | 0% |
Wie hat sich ARX auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/07/06 12:26 |
| Aktienkurs zum Tagesende | 2026/07/06 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2026/03/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Aroa Biosurgery Limited wird von 4 Analysten beobachtet. 3 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| John Hester | Bell Potter |
| Shane Storey | Canaccord Genuity |
| Scott Power | Morgans Financial Limited |